Exosla Therapeutics appoints seasoned biotech executive Dr Jens Kurth as CEO and emerges out-of-stealth mode

 Exosla strengthens senior leadership team to accelerate the path to the clinic and market

Exosla Therapeutics, Cambridge (UK) and Essen (Germany), 11th June 2024: Exosla Therapeutics, a UK/German biotech offering safe and scalable multimodal immunotherapies, is delighted to announce the appointment of Jens Kurth, PhD as Chief Executive Officer.

Dr. Jens Kurth is a seasoned biotech executive with nearly 30 years of experience in translating innovative therapies into development, regulating, and commercialising new drugs globally across both biotech startups and large pharmaceutical companies. He co-founded several VC-funded biotech startups and secured over $90 million in funding, notably raising $39 million for Vivet Therapeutics. His career also includes significant tenures at Miltenyi, Novartis, and Baxter, where he led global business operations and contributed to major advancements in biologics, cell and gene-based therapies, as well as immuno-oncology treatments. Dr. Kurth received his PhD and MSc in Biochemistry from the University of Cologne.

Jens Kurth commented of his appointment: “I am thrilled to join Exosla Therapeutics to support the company in advancing its innovative extracellular vesicle-based therapy to the clinic and market for patients in medical need. The preclinical data generated by Professor Bernd Giebel at the University of Duisburg-Essen are exciting and pave the way for treating many immune-related diseases. Exosla’s multimodal immunotherapy can be scaled rapidly and holds promise in the fields of neurodegeneration, ophthalmology and auto-immune diseases”

Pierre Arsène, Founder and Chair, Exosla Therapeutics added: “Exosla’s ambition is to bring rigorously controlled and scalable regenerative medicine to the market, opening new ways of dealing with diseases and aging. Jens’s impressive track record in scaling biotech startups and bringing breakthrough therapies to market is a perfect fit. I am excited to welcome him to the team as Exosla accelerates its journey to reach patients.”

Exosla is coincidentally emerging from stealth mode after years of de-risking. This announcement is made on the day of its participation in BioSeed Summer 2024, one of the leading UK investor meetings for early-stage biotech. Exosla aims to submit an Investigational New Drug (IND) application in 18 months.

About Exosla Therapeutics

Exosla Therapeutics is a UK/German pre-clinical biotech company focused on immune-related diseases, including ocular neuroinflammation. It offers a safe and scalable immunotherapy by leveraging the multimodal action of ​high-performing extracellular vesicles (EVs) from specific monoclonal mesenchymal stem/stromal cell (MSC) lines, which were previously immortalised to supply the full drug life cycle. The scientific and translational efforts are built on over a decade of foundational work by Prof. Bernd Giebel at the University of Duisburg-Essen, a pioneer in the MSC-EV field.

Discover more: exosla.com

-ENDS-

 

MEDIA RELATIONS

For more information contact:

Exosla Therapeutics, Cambridge, U.K.

Tel: +44 (0) 1223 928 141

Exosla Therapeutics, Essen, Germany

Tel: +49 (0) 201 723 4204

Email: contact@exosla.com